EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platform
A new DNA sequencing tool catches more hidden cancer mutations than standard tests, particularly in hard-to-read regions, helping doctors find genetic drivers they might otherwise miss.
EXaCT-2 is a validated whole-exome sequencing platform that combines comprehensive genomic breadth with targeted-panel depth for 1,400+ cancer genes, enabling simultaneous detection of SNVs, indels, SCNAs, fusions, TMB, MSI, oncogenic viruses, and BCR clonotypes. In 244 matched tumor/normal pairs, EXaCT-2 demonstrated superior sensitivity for sub-clonal mutations versus standard exome assays, with particular benefit for GC-rich drivers like KRAS.
What the study was
- Study design
- Benchmarking and validation study
- Population
- Cancer patients (solid tumor cohort)
- Sample size
- 244
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- NPJ Precision Oncology
Why it surfaced
Weill Cornell comprehensive WES platform with clinical validation in 244 pairs; enables unified genomic profiling replacing need for multiple assays; near-term implementable for cancer centers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.